Genitourinary Cancers

Nikhil A. Gopal, MD, discusses the transition of treatment with TKIs to treatment with TKI/IO combinations for those with renal cell carcinoma.

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

Neoadjuvant tislelizumab plus axitinib demonstrated clinical efficacy and safety in patients with nonmetastatic clear cell renal cell carcinoma.

Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.

Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.

Brian I. Rini, MD, FASCO, discusses the background that led to the FDA approval of belzutifan for patients with advanced renal cell carcinoma.

Nikhil A. Gopal, MD, discusses the benefit of belzutifan in addition to effective immunotherapy-based regimens in advanced RCC.

Nikhil A. Gopal, MD, discusses the benefit of belzutifan for patients with renal cell carcinoma.

Jaime R. Merchán, MD, discusses the role of pembrolizumab plus axitinib or lenvatinib in previously untreated advanced renal cell carcinoma.

Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.

Brian I. Rini, MD, FASCO, discusses the research that led to the FDA approval of belzutifan for patients with advanced renal cell carcinoma.

Kathryn Beckermann, MD, PhD, discusses the treatment of PY314 in combination with pembrolizumab in patients with clear cell renal cell carcinoma.

Eleonora Dondossola, PhD, discusses the importance of studying bone metastasis in RCC and other genitourinary cancers.

Tian Zhang, MD, MHS, discusses the implications of subgroup analyses from the KEYNOTE-564 trial in patients with renal cell carcinoma.

Benjamin Garmezy, MD, discusses in when to choose an IO/TKI regimen for the treatment of patients with ccRCC.

Tian Zhang, MD, MHS, discusses using the adjuvant KEYNOTE-564 regimen to treat high-risk patients with renal cell carcinoma.

Frontline nivolumab plus cabozantinib continued to demonstrate long-term efficacy and safety vs sunitinib in patients with untreated RCC.

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Daniel J. George, MD, discusses the phase 3b CheckMate 8Y8 study of nivolumab plus ipilimumab vs nivolumab alone in previously untreated advanced RCC

Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study.

Emily Arner, PhD, discusses research on the role of SETD2 loss in metastatic clear cell renal cell carcinoma ccRCC.